Literature DB >> 12799502

Risk factors for bronchiolitis-associated deaths among infants in the United States.

Robert C Holman1, David K Shay, Aaron T Curns, Jairam R Lingappa, Larry J Anderson.   

Abstract

BACKGROUND: Risk factors for bronchiolitis deaths have not been described on a national level. We examined the epidemiology of and identified risk factors for bronchiolitis-associated deaths among infants in the United States.
METHODS: Multiple cause-of-death and linked birth/infant death data for 1996 through 1998 were used to examine bronchiolitis-associated infant deaths. Risk factors were assessed by comparing infants who died with bronchiolitis and surviving infants.
RESULTS: During 1996 through 1998 there were 229 bronchiolitis infant deaths, resulting in an average annual infant mortality rate of 2.0 per 100 000 live births. The majority (55%) of infant deaths occurred among infants ages 1 through 3 months. The bronchiolitis mortality rate was highest among infants weighing <1500 g at birth (VLBW) as compared with infants weighing 1500 to 2499 g (LBW) and > or =2500 g at birth (29.8, 6.4 and 1.3 per 100 000 live births, respectively). Sixty-three percent of bronchiolitis deaths were among infants weighing > or =2500 g. VLBW and LBW infants remained at an increased risk of dying with bronchiolitis after controlling for other risk factors. Other risk factors included increasing birth order, low 5-min Apgar score, young maternal age, unmarried mother and tobacco use during pregnancy.
CONCLUSIONS: VLBW and LBW infants are at increased risk of dying with bronchiolitis, even when taking into account other risk factors. Although infants weighing <2500 g at birth are at increased risk for dying with bronchiolitis, the majority of bronchiolitis deaths occur among infants of normal birth weight.

Entities:  

Mesh:

Year:  2003        PMID: 12799502     DOI: 10.1097/01.inf.0000069765.43405.3b

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  45 in total

Review 1.  Respiratory morbidity and lung function in preterm infants of 32 to 36 weeks' gestational age.

Authors:  Andrew A Colin; Cynthia McEvoy; Robert G Castile
Journal:  Pediatrics       Date:  2010-06-07       Impact factor: 7.124

2.  Risk factors for hospitalization due to respiratory syncytial virus infection among infants in the Basque Country, Spain.

Authors:  G Cilla; A Sarasua; M Montes; N Arostegui; D Vicente; E Pérez-Yarza; E Pérez-Trallero
Journal:  Epidemiol Infect       Date:  2006-06       Impact factor: 2.451

Review 3.  Respiratory syncytial virus bronchiolitis.

Authors:  Alexander K C Leung; James D Kellner; H Dele Davies
Journal:  J Natl Med Assoc       Date:  2005-12       Impact factor: 1.798

4.  A decade of respiratory syncytial virus epidemiology and prophylaxis: translating evidence into everyday clinical practice.

Authors:  Bosco A Paes; Ian Mitchell; Anna Banerji; Krista L Lanctôt; Joanne M Langley
Journal:  Can Respir J       Date:  2011 Mar-Apr       Impact factor: 2.409

5.  Risk factors for infectious disease death among infants in the United States.

Authors:  Marissa K Person; Douglas H Esposito; Robert C Holman; Jason M Mehal; Barbara J Stoll
Journal:  Pediatr Infect Dis J       Date:  2014-11       Impact factor: 2.129

6.  Respiratory Syncytial Virus Prophylaxis in Special Populations: Is it Something Worth Considering in Cystic Fibrosis and Immunosuppression?

Authors:  William A Prescott; David J Hutchinson
Journal:  J Pediatr Pharmacol Ther       Date:  2011-04

7.  Predictors and incidence of hospitalization due to respiratory syncytial virus (RSV)-associated lower respiratory tract infection (LRTI) in non-prophylaxed moderate-to-late preterm infants in Bosnia and Herzegovina.

Authors:  Hajrija Maksić; Suada Heljić; Fahrija Skokić; Darinka Šumanović-Glamuzina; Veroslava Milošević; Almir Zlatanović; Notario Gerard
Journal:  Bosn J Basic Med Sci       Date:  2018-08-01       Impact factor: 3.363

8.  Prophylaxis of respiratory syncytial virus in Canada in 2003.

Authors:  Joan L Robinson; Bonita E Lee
Journal:  Paediatr Child Health       Date:  2003-12       Impact factor: 2.253

9.  Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009.

Authors:  Seung Gu Chang; Moon Sung Park; Jae Eun Yu
Journal:  J Korean Med Sci       Date:  2010-01-19       Impact factor: 2.153

10.  Respiratory viruses in bronchiolitis and their link to recurrent wheezing and asthma.

Authors:  Jonathan M Mansbach; Carlos A Camargo
Journal:  Clin Lab Med       Date:  2009-12       Impact factor: 1.935

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.